Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pu Ping Qing Hua Formula is a Traditional Chinese Medicine (TCM) herbal preparation developed by Renji Hospital, affiliated with the Shanghai Jiaotong University School of Medicine. It is designed for the treatment of COVID-19, specifically aimed at accelerating the negative conversion of SARS-CoV-2 nucleic acid in infected patients. The formula is typically administered orally and has been evaluated in prospective, randomized controlled trials comparing its efficacy to other established TCM treatments like Lianhuaqingwen granules. As a complex herbal mixture, its therapeutic effects are likely mediated through a combination of anti-viral, anti-inflammatory, and immunomodulatory mechanisms characteristic of heat-clearing and dampness-transforming TCM strategies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on puping qinghua formula.